Format

Send to

Choose Destination
Ann Intern Med. 2002 May 21;136(10):742-6.

Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial.

Author information

1
University of Pittsburgh Osteoporosis Prevention & Treatment Center, 1110 Kaufmann Building, 3471 Fifth Avenue, Pittsburgh, PA 15213, USA.

Abstract

BACKGROUND:

Many elderly female residents of long-term care facilities have osteoporosis and could benefit from intervention to increase bone density.

OBJECTIVE:

To examine the efficacy and safety of alendronate for treatment of osteoporosis in elderly female residents of long-term care facilities.

DESIGN:

Multicenter, randomized, double-blind, placebo-controlled 2-year study.

SETTING:

25 long-term care facilities.

PATIENTS:

327 elderly women with osteoporosis.

INTERVENTION:

Patients were randomly assigned to receive alendronate, 10 mg/d, or placebo. All patients also received vitamin D, 400 IU/d, and some patients received supplemental calcium (total intake, approximately 1500 mg/d).

MEASUREMENTS:

Bone mineral density (BMD) of the spine and hip and biochemical markers of bone turnover.

RESULTS:

Alendronate produced significantly greater increases in BMD than did placebo (24-month differences: spine, 4.4% [95% CI, 3.3% to 5.5%]; femoral neck, 3.4% [CI, 2.3% to 4.4%]). Alendronate produced greater decreases from baseline in biochemical markers of bone turnover than did placebo (P < 0.001).

CONCLUSION:

Alendronate increased BMD at both the spine and hip in elderly female residents of long-term care facilities.

PMID:
12020142
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center